Medico Remedies Ltd (MEDICO) — FY26 Annual Report | 29 August 2026 (2 announcements)

Medico Remedies Limited submitted its Annual Report 2025-26 along with notice of the 32nd AGM on August 29, 2026. The report covers full-year performance, strategic direction, and material risks. Key highlights include FY2025-26 revenue of ₹21,231 lakhs (up from ₹15,363 lakhs), profit after tax of ₹1,311 lakhs (up from ₹1,009 lakhs), and no dividend declared. The AGM scheduled for September 22, 2026 will reappoint Haresh Mehta as Chairman & Whole-Time Director and Rishit Mehta as Whole-Time Director for three years, and increase remuneration for Harshit Mehta (Managing Director) and Priyal Mehta (Professional Consultant) and Shweta Mehta (Regulatory Deputy Manager). The report details board composition, governance practices, risk management, CSR initiatives, and compliance with SEBI and MCA regulations. Material changes include reappointments, remuneration increases, and new director appointments. Key risks involve foreign exchange volatility, regulatory changes, and operational challenges in manufacturing.

Medico Remedies Limited submitted its Annual Report 2025-26 to BSE on 29 August 2026, covering FY ending 31 March 2026. The report includes AGM notice for 22 September 2026 (VC mode), director reappointments (Haresh Mehta, Rishit Mehta, Harshit Mehta), remuneration details, dividend policy (no dividend), financial highlights (Revenue: ₹21,231 lakhs; PAT: ₹1,311 lakhs), risk disclosures, CSR spending (₹27 lakhs), and compliance with SEBI/LODR regulations. Key governance updates include new director appointments, internal auditor changes, and whistleblower policy compliance.